U.S. Court of Appeals for the Federal Circuit
Endo Pharmaceuticals Inc. v. Actavis LLC
This writing
- Type
- Dissent
- Filed
- May 3, 2019
- Case
- Endo Pharmaceuticals Inc. v. Actavis LLC
- Case status
- Decided
Source No authoring judge could be established for this writing, either from provider metadata or from the signature line of the court's published opinion. Benchlight shows the gap rather than guessing at an author.
Opening text
The first passage of the document, as extracted by the source provider.
Stoll, Circuit Judge, dissenting. I respectfully dissent. The FDA set a regulatory requirement that ABUK content in oxymorphone products be less than 0.001% (10 ppm). Mallinckrodt then claimed this requirement in the '779 patent. Not only does the FDA's mandate disclose every limitation of claim 1, but it is the only prior art reference that discloses the 0.001% oxymorphone ABUK limitation. Compare J.A. 2736, 2895, wit…
Source Extract supplied by CourtListener. Benchlight does not host the document — read the authoritative text in the court's own PDF.
Other writings in this case
| Type | Author | Filed |
|---|---|---|
| Opinion of the Court | Not attributed | May 3, 2019 |
| Opinion | Not attributed | May 3, 2019 |